Dongsheng Tu
机构: Professor of Biostatistics, Queen's University at Kingston, Canada
每年引用次数
引用次数
引用: 50,542
H-指数: 84
I10-指数 : 235
出版物: 544
Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17
Edith A. Perez , Robert G. Josse , Kathleen I. Pritchard , James N. Ingle
Journal of Clinical Oncology 24 ( 22) 3629 -3635
255
2006
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
Mark N. Levine , Kathleen I. Pritchard , Vivien H.C. Bramwell , Lois E. Shepherd
Journal of Clinical Oncology 23 ( 22) 5166 -5170
181
2005
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
Timothy J. Whelan , Paul E. Goss , James N. Ingle , Joseph L. Pater
Journal of Clinical Oncology 23 ( 28) 6931 -6940
206
2005
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
John Goffin , Stefan Baral , Dongsheng Tu , Dora Nomikos
Clinical Cancer Research 11 ( 16) 5928 -5934
75
2005
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Christos S Karapetis , Derek Jonker , Manijeh Daneshmand , Jennifer E Hanson
Clinical Cancer Research 20 ( 3) 744 -753
111
2014
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Maggie C.U. Cheang , K. David Voduc , Dongsheng Tu , Shan Jiang
Clinical Cancer Research 18 ( 8) 2402 -2412
114
2012
A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Lois E. Shepherd , Shan Jiang , Tammi Vickery , Elaine Mardis
Clinical Cancer Research 18 ( 16) 4465 -4472
200
2012
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
Jeffrey S. Hoch , Annette Hay , Wanrudee Isaranuwatchai , Kednapa Thavorn
BMC Cancer 19 ( 1) 552
2019
Joint analysis of longitudinal measurements and survival times with a cure fraction based on partly linear mixed and semiparametric cure models
Lu Yang , Hui Song , Yingwei Peng , Dongsheng Tu
Pharmaceutical Statistics 20 ( 2) 362 -374
4
2021
Abstract B97: Vitamin D and mammographic density in postmenopausal women: A cohort study nested within the NCIC CTG MAP.3 chemoprevention trial
Ralph Meyer , Will King , Melanie Walker , Harriet Richardson
Cancer Prevention Research 5
2012
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss , James N. Ingle , José E. Alés-Martínez , Angela M. Cheung
The New England Journal of Medicine 364 ( 25) 2381 -2391
684
2011
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul E. Goss , James N. Ingle , Kathleen I. Pritchard , Nicholas J. Robert
The New England Journal of Medicine 375 ( 3) 209 -219
301
2016
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker , Chris J. O'Callaghan , Christos S. Karapetis , John R. Zalcberg
The New England Journal of Medicine 357 ( 20) 2040 -2048
2,322
2007
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S. Karapetis , Shirin Khambata-Ford , Derek J. Jonker , Chris J. O'Callaghan
The New England Journal of Medicine 359 ( 17) 1757 -1765
2,961
2008
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Christine M. Ribic , Daniel J. Sargent , Malcolm J. Moore , Stephen N. Thibodeau
The New England Journal of Medicine 349 ( 3) 247 -257
2,570
2003
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss , James N. Ingle , Silvana Martino , Nicholas J. Robert
New England Journal of Medicine 349 ( 19) 1793 -1802
1,493
2003
Morphine, Gabapentin, or Their Combination for Neuropathic Pain
J Kenneth Baillie , Ian Power , Solomon Tesfaye , Dinesh Selvarajah
The New England Journal of Medicine 352 ( 13) 1324 -1334
1,391
2005
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd , José Rodrigues Pereira , Tudor Ciuleanu , Eng Huat Tan
The New England Journal of Medicine 353 ( 2) 123 -132
6,918
2005
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Kathleen I. Pritchard , Lois E. Shepherd , Frances P. O'Malley , Irene L. Andrulis
The New England Journal of Medicine 354 ( 20) 2103 -2111
460
2006
Accurate Confidence Intervals for the Ratio of Specific Occurrence/Exposure Rates in Risk and Survival Analysis
Dongsheng Tu , Alan J. Gross
Biometrical Journal 37 ( 5) 611 -626
2
1995
Lois Shepherd Lesley Seymour Kathleen I. Pritchard C Karapetis John Zalcberg Jeremy Shapiro Timothy Price Christopher J O'Callaghan Michael Brundage Wendy R. Parulekar Ian Gilron John Goffin Lillian Siu Ronald R. Holden Nancy E Davidson Penelope Bradbury Stephen KL Chia Zee Chung-Ying Benny Ming Tsao Sharlene Gill